Drugs / RYZ401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07165132 | Dec 2025 → Feb 2027 expected | carcinoid tumor, pancreatic neuroendocrine tumor | RayzeBio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RYZ401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07165132 ↗ |
| Modality | Other / unclassified | “a Novel Radiopharmaceutical Therapy Labeled With Actinium-225” NCT07165132 ↗ |